The global viral inactivation market size is estimated to reach USD 1.37 billion by 2030, registering a CAGR of 11.58% from 2025 to 2030
Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.
Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.
Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.
Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the viral inactivation market.
Viral Inactivation Market Report Highlights
The kits & reagents product segment led the market with the largest revenue share of 57.37% in 2024, attributed to the rise in biopharmaceutical and biotechnological companies worldwide.
By application, the vaccines and therapeutics segment held the largest revenue share of 34.41% in 2024, attributed to the rising investments in R&D applications such as gene therapy and stem cell research.
In 2024, the pharmaceutical and biotechnology companies segment led the market with the largest revenue share of 38.51%, attributed to the growth of pharmaceutical and biopharmaceutical companies.
North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases.
Chapter 5. Viral Inactivation Market: Application Estimates & Trend Analysis 5.1. Application Segment Dashboard 5.2. Global Viral Inactivation Market Application Movement Analysis 5.3. Global Viral Inactivation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million) 5.4. Vaccines & Therapeutics 5.5. Stem Cell Products 5.6. Blood & Blood Products 5.7. Tissue/ Tissue Products 5.8. Cellular and Gene Therapy
Chapter 6. Viral Inactivation Market: End Use Estimates & Trend Analysis 6.1. End Use Segment Dashboard 6.2. Global Viral Inactivation Market End Use Movement Analysis 6.3. Global Viral Inactivation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million) 6.4. Pharmaceutical & Biotechnological Companies 6.4.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million) 6.5. CROs 6.6. Academic and Research Institutes 6.7. Others
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
EU Venture Capital is a premier platform providing in-depth insights, funding opportunities, and market analysis for the European startup ecosystem. Wholly owned by EU Startup News, it connects entrepreneurs, investors, and industry professionals with the latest trends, expert resources, and exclusive reports in venture capital.
